Kwangdong Pharmaceutical Announces New Research Proving Gyeongokgo's Efficacy for Menopausal Disorders

Kwangdong Pharmaceutical announced on the 12th that new research results on the efficacy of Gyeongokgo for menopausal disorders have been published.

According to Kwangdong Pharmaceutical, a paper titled "Improvement Effects of Gyeongokgo and Gyeongokgo-Galgeun Mixture on Postmenopausal Osteoporosis through Promotion of Phytoestrogen Activity in Rats" was published in the international journal Frontiers in Nutrition. The paper confirmed that Gyeongokgo showed improvement effects on representative menopausal symptoms in animal experiments, such as hot flashes, decreased osteoblast activity, and increased blood lipids.

The study, conducted over 14 months from May 2021, administered Kwangdong Gyeongokgo orally to experimental rats for 3 months (12 weeks). In rats induced into menopause, daily oral administration of a fixed amount of Gyeongokgo resulted in significant outcomes including: ▲a decrease in tail skin temperature compared to the control group (5.5%↓), ▲an increase in the amount of serum osteocalcin, a representative biomarker of osteoblast activity (menopause-induced group: 8.80 ± 1.18 ng/mL, Gyeongokgo intake group: 12.91 ± 1.46 ng/mL), and ▲improvement in blood lipid (LDL) increase caused by decreased estrogen levels (menopause-induced group: 109.6 ± 54.0 mg/dL, Gyeongokgo intake group: 92.3 ± 41.2 mg/dL).

Kwangdong Pharmaceutical has academically proven the efficacy of Gyeongokgo through studies on anti-fatigue effects (2016, Journal of Pharmacognosy), immune enhancement effects (2019, Korean Journal of Herbology), and menopausal syndrome (2020, Journal of Pharmacognosy). In 2019, a study on the inhibitory effect of Gyeongokgo on inflammation caused by fine dust was published in the SCI-level international journal International Journal of Environmental Health Research. In experiments conducted on mice, Gyeongokgo significantly reduced the increased vascular permeability caused by fine dust.

A Kwangdong Pharmaceutical official stated, "This study is an additional confirmation of effects following the 2020 research on cognitive function and depression improvement in menopausal syndrome," adding, "We will continue to support product efficacy with scientific evidence through various research results."

Photo of Kwangdong Pharmaceutical's 'Kwangdong Gyeongokgo' product. [Photo by Kwangdong Pharmaceutical]

This content was produced with the assistance of AI translation services.